Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022

2022; European Centre for Disease Prevention and Control; Volume: 27; Issue: 37 Linguagem: Inglês

10.2807/1560-7917.es.2022.27.37.2200697

ISSN

1560-7917

Autores

Irina Kislaya, Ausenda Machado, Sarah Magalhães, Ana Paula Rodrigues, Rafael Franco, Pedro Pinto Leite, Carlos Matias Dias, Baltazar Nunes,

Tópico(s)

Long-Term Effects of COVID-19

Resumo

We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in ≥ 80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death.

Referência(s)